INSM

Insmed is a biopharmaceutical company focused on developing innovative therapies for serious and rare diseases, particularly those affecting the lungs and metabolic systems. Its lead product, ARIKAYCE, is used to treat chronic lung infections.

The company's pipeline includes brensocatib, a treatment for bronchiectasis, and an inhaled formulation of treprostinil for pulmonary arterial hypertension. With global operations and research hubs in the U.S. and UK, Insmed is dedicated to improving outcomes for patients with limited treatment options.